Drug
ITCA 650 60 mcg/day
ITCA 650 60 mcg/day is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Withdrawn2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
completed133%
withdrawn267%
Recent Activity
0 active trials
Showing 3 of 3
completedphase_3
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
NCT01455870
withdrawnphase_3
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
NCT01455909
withdrawnphase_3
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
NCT01455883
Clinical Trials (3)
Showing 3 of 3 trials
NCT01455870Phase 3
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
NCT01455909Phase 3
A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes
NCT01455883Phase 3
A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3